![Mitchell Chan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 973 332 $ al 30/09/2026
Dr. Mitchell Chan is a Chief Financial Officer at REGENXBIO, Inc. He is on the Board of Directors at Maryland Technology Council.
Dr. Chan was previously employed as an Independent Director by Avalo Therapeutics, Inc., an Operating Partner by Catalio Capital Management LP, a Chief Financial & Accounting Officer by Viela Bio, Inc., and a Director-Investor Relations by AstraZeneca PLC.
He received his undergraduate degree from the University of Toronto, a graduate degree from the University of Toronto and an MBA from Rotman School of Management.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
REGENXBIO, INC. 0,19 % | 01/09/2026 | 122.815 ( 0,19 % ) | 924 797 $ | 30/09/2026 |
AVALO THERAPEUTICS INC 0,01 % | 06/05/2026 | 3.166 ( 0,01 % ) | 48 535 $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| REGENXBIO INC. | Director Financiero/CFO | 16/09/2024 |
Maryland Technology Council
 Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services Function as technology trade association | Director/Miembro de la Junta | 11/03/2020 |
| Empresas | Cargo | Fin |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Director/Miembro de la Junta | 02/06/2026 |
| VIELA BIO, INC. | Director Financiero/CFO | 15/03/2021 |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Corporate Officer/Principal | 01/03/2021 |
| ASTRAZENECA PLC | Contacto de Relaciones con Inversores | 01/09/2018 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 8 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Rotman School of Management
 Rotman School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
REGENXBIO, Inc.
 REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avalo Therapeutics, Inc.
 Avalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases | Health Technology |
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services Function as technology trade association | Commercial Services |
Viela Bio, Inc.
 Viela Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company that develops treatments for inflammation and autoimmune diseases | Health Technology |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Finance |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
